The recurrent mutations suggest that Mtor and Sdk1 may also function as cancer drivers in NASH-HCC, while other recurrently mutated genes could represent novel candidates associated with NASH-HCC. This evidence concerns the gene MTOR and metabolic dysfunction-associated steatohepatitis.